15 March 2024
EMA/114981/2024
Committee for Veterinary Medicinal Products (CVMP)

**Summary of opinion[1] (post-authorisation)**

# Prevexxion RN+HVT+IBD

## Common name: Infectious bursal disease and Marek's disease vaccine (live recombinant)

On 12-13 March 2024 the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion[2], recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Prevexxion RN+HVT+IBD. The marketing authorisation holder for this veterinary medicinal product is Boehringer Ingelheim Vetmedica GmbH.

Prevexxion RN+HVT+IBD is currently authorised as concentrate and solvent for suspension for injection. The variation concerns the addition of a new route of administration: in ovo.

Detailed conditions for the use of this product are described in the updated summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

[1] Summaries of opinion are published without prejudice to the Commission Decision.
[2] Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

**Official address** Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
**Address for visits and deliveries** Refer to www.ema.europa.eu/how-to-find-us
**Send us a question** Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union